Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naive or Switching Patients: A Systematic Review.

ABSTRACT:

Introduction

In 2016, SB4 (Benepali^®) became the first etanercept (ETN) biosimilar to obtain marketing authorisation in Europe. Despite robust analytical and clinical comparisons, outstanding questions remain on SB4 use in routine practice.

Methods

A systematic search for publications on real-world evidence of SB4 effectiveness, safety and drug survival was undertaken using search terms (SB4 OR Benepali OR biosimilar etanercept OR innovator etanercept) in the BIOSIS^® Toxicology, BIOSIS Previews^®, Embase^® and MEDLINE^® databases up to 17 January 2019.

Results

Of 959 articles identified, eight journal articles, two journal letters and 23 congress abstracts were selected on criteria of original real-world evidence wit

SUBMITTER: Ebbers HC 

PROVIDER: S-EPMC6702587 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature